<DOC>
	<DOCNO>NCT02239926</DOCNO>
	<brief_summary>Will Ranolazine improve bowel function abdominal pain human subject IBS-D ?</brief_summary>
	<brief_title>Effect Ranolazine Gastrointestinal Motor Function Pain Patients With IBS-D</brief_title>
	<detailed_description>This randomized double-blind placebo-controlled pilot study use validate bowel questionnaire evaluate effect ranolazine administer orally twice daily patient diarrhea predominant IBS ( IBS-D ) . The study consist 2 week run period , follow 4 week treatment period oral ranolazine 1000 mg twice daily . Primary endpoint study average Bowel Symptom Scale ( BSS ) score diarrhea adequate relief IBS pain discomfort secondary end point .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Inclusion Criteria Males nonpregnant , nonbreastfeeding female establish diagnosis IBSD modify Rome III criterion ( Abdominal Pain Intensity : weekly average bad daily score &gt; 3.0 0 10 point scale Stool Consistency : least one stool consistency Type 5 , 6 7 Bristol stool score least 2 day per week ) 1870 year old U.S. resident Englishspeaking ( provide consent complete questionnaire ) Exclusion Criteria Structural metabolic diseases/conditions affect gastrointestinal system Unable withdraw follow medication 48 hour prior study : Drugs alter GI transit include Lomotil , bile acid binder cholestyramine , prokinetics ( e.g . metoclopramide , cisapride erythromycin ) , narcotic ( e.g . oxycodone , morphine ) anticholinergic ( dicyclomine , hyoscyamine ) . Analgesic drug include narcotic , NSAID , cyclooxygenase2 ( COX2 ) inhibitor ( celecoxib , rofecoxib , valdecoxib ) GABAergic agent ( baclofen ) Benzodiazepines ( e.g . lorazepam , alprazolam , diazepam ) . Low stable dos thyroid replacement , estrogen replacement , low dose aspirin cardioprotection birth control pills depot injection permissible . Unable withdraw follow medication , contraindication ranolazine : Strong Cytochrome P450 , Family 3 , Subfamily A ( CYP3A ) inhibitor ( e.g . ketoconazole , clarithromycin , nelfinavir ) CYP3A inducer ( e.g . rifampin , phenobarbital , St. John 's wort ) Female subject pregnant breastfeeding . Current symptom severe depression , measure Hospital Anxiety And Depression Scale ( HADS ) score great 15 . Clinical evidence ( include physical exam , ECG , laboratory study review medical history ) significant cardiovascular , respiratory , renal , hepatic , gastrointestinal , hematological , neurological , psychiatric , disease interfere objective study . The Corrected QT Interval ( QTc ) &gt; 490 msec . Active alcoholic remission know substance abuser . Liver cirrhosis Patients clinically significant hepatic disease . Major cardiovascular event last 6 month . Participation another clinical trial ( within 30 day ) . Incarcerated .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>IBS-D</keyword>
</DOC>